Amneal Pharmaceuticals, Inc. $AMRX Stock: Profund Advisors LLC Increases Holdings

Profund Advisors LLC lifted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 279.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 96,883 shares of the company’s stock after acquiring an additional 71,343 shares during the quarter. Profund Advisors LLC’s holdings in Amneal Pharmaceuticals were worth $1,951,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Vise Technologies Inc. raised its position in shares of Amneal Pharmaceuticals by 21.1% during the third quarter. Vise Technologies Inc. now owns 33,200 shares of the company’s stock worth $669,000 after purchasing an additional 5,780 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Amneal Pharmaceuticals by 25.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 63,550 shares of the company’s stock valued at $1,284,000 after purchasing an additional 12,777 shares during the period. Park Avenue Securities LLC boosted its position in shares of Amneal Pharmaceuticals by 28.1% in the 3rd quarter. Park Avenue Securities LLC now owns 15,668 shares of the company’s stock valued at $316,000 after purchasing an additional 3,436 shares during the period. Gibbs Wealth Management acquired a new position in shares of Amneal Pharmaceuticals in the 3rd quarter valued at $613,000. Finally, Sterling Capital Management LLC increased its stake in Amneal Pharmaceuticals by 30.3% in the 3rd quarter. Sterling Capital Management LLC now owns 3,549 shares of the company’s stock worth $71,000 after purchasing an additional 825 shares in the last quarter. 31.82% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on AMRX. The Goldman Sachs Group restated a “buy” rating and issued a $24.00 target price on shares of Amneal Pharmaceuticals in a report on Thursday. Oppenheimer began coverage on Amneal Pharmaceuticals in a research report on Wednesday, September 23rd. They set an “outperform” rating and a $27.00 price objective for the company. Weiss Ratings raised Amneal Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. UBS Group reiterated a “buy” rating on shares of Amneal Pharmaceuticals in a report on Thursday, October 1st. Finally, Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.86.

Insider Activity at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director John Kiely sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $17.64, for a total value of $882,000.00. Following the completion of the sale, the director directly owned 210,252 shares in the company, valued at $3,708,845.28. The trade was a 19.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Nikita Shah sold 146,403 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the completion of the sale, the executive vice president directly owned 253,390 shares of the company’s stock, valued at $4,436,858.90. This represents a 36.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 413,016 shares of company stock valued at $7,216,567. 17.30% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Price Performance

AMRX opened at $21.51 on Monday. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $10.06 and a fifty-two week high of $21.68. The business has a 50-day moving average of $19.12 and a 200-day moving average of $15.74. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. The company has a market capitalization of $6.87 billion, a PE ratio of 43.90, a price-to-earnings-growth ratio of 2.51 and a beta of 1.22.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.24 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%. The business had revenue of $796.20 million during the quarter. Equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.95 EPS for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.